ADPT vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADPT's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 1/9 indicates extreme weakness, with no positive signals in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative ROE (-27.82%), negative operating margin (-17.82%), and high debt/equity (0.93) suggest significant distress risk. Despite strong revenue growth (51% YoY) and a history of earnings surprises, the stock trades at a forward P/E of -48.78, reflecting deep losses and speculative valuation. Insider selling totaling $12.73M in six months further undermines confidence, signaling potential internal skepticism about near-term prospects.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADPT vs LLY: Head-to-Head Comparison
This page compares Adaptive Biotechnologies Corporation (ADPT) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.